Literature DB >> 20824007

Assessment of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in Breast Cancer Tissue: Historical Aspects and Future Prospects.

Manfred Schmitt1, Karin Mengele, Apostolos Gkazepis, Rudolf Napieralski, Viktor Magdolen, Ute Reuning, Nadia Harbeck.   

Abstract

Entities:  

Year:  2008        PMID： 20824007      PMCID： PMC2930995          DOI： 10.1159/000151737

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN： 1661-3791            Impact factor:   2.860


× No keyword cloud information.
  71 in total

1.  Purification and characterization of a plasminogen activator secreted by cultured human pancreatic carcinoma cells.

Authors:  M Wu; G K Arimura; A A Yunis
Journal:  Biochemistry       Date:  1977-05-03       Impact factor: 3.162

2.  Prognostic value of PAI1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression.

Authors:  Mark D Sternlicht; Alison M Dunning; Dan H Moore; Paul D P Pharoah; David G Ginzinger; Koei Chin; Joe W Gray; Frederic M Waldman; Bruce A J Ponder; Zena Werb
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-11       Impact factor: 4.254

3.  Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer.

Authors:  F Jänicke; M Schmitt; H Graeff
Journal:  Semin Thromb Hemost       Date:  1991-07       Impact factor: 4.180

4.  Fibrinolysis; its mechanism and significance.

Authors:  R G MACFARLANE; R BIGGS
Journal:  Blood       Date:  1948-10       Impact factor: 22.113

5.  Blood clotting and related processes.

Authors:  T ASTRUP
Journal:  Adv Enzymol Relat Subj Biochem       Date:  1950

Review 6.  Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.

Authors:  D F Hayes; R C Bast; C E Desch; H Fritsche; N E Kemeny; J M Jessup; G Y Locker; J S Macdonald; R G Mennel; L Norton; P Ravdin; S Taube; R J Winn
Journal:  J Natl Cancer Inst       Date:  1996-10-16       Impact factor: 13.506

7.  A group of patients with impaired plasma fibrinolytic system and selective inhibition of tissue activator-induced fibrinolysis.

Authors:  P Brakman; E R Mohler; T Astrup
Journal:  Scand J Haematol       Date:  1966

8.  Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.

Authors:  Julia C Biermann; Leon Holzscheiter; Matthias Kotzsch; Thomas Luther; Marion Kiechle-Bahat; Fred C G J Sweep; Paul N Span; Manfred Schmitt; Viktor Magdolen
Journal:  Int J Mol Med       Date:  2008-02       Impact factor: 4.101

9.  Procedures for the quantitative protein determination of urokinase and its inhibitor, PAI-1, in human breast cancer tissue extracts by ELISA.

Authors:  Manfred Schmitt; Alexandra S Sturmheit; Anita Welk; Christel Schnelldorfer; Nadia Harbeck
Journal:  Methods Mol Med       Date:  2006

10.  Isolation from human plasma of a plasminogen activator identical to urinary high molecular weight urokinase.

Authors:  J D Tissot; P Schneider; J Hauert; M Ruegg; E K Kruithof; F Bachmann
Journal:  J Clin Invest       Date:  1982-12       Impact factor: 14.808
View more
  9 in total

1.  Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up.

Authors:  Marko Buta; Radan Džodić; Igor Đurišić; Ivan Marković; Tijana Vujasinović; Milan Markićević; Dragica Nikolić-Vukosavljević
Journal:  Tumour Biol       Date:  2015-05-21

2.  uPA and PAI-1-Related Signaling Pathways Differ between Primary Breast Cancers and Lymph Node Metastases.

Authors:  Katharina Malinowsky; Claudia Wolff; Daniela Berg; Tibor Schuster; Axel Walch; Holger Bronger; Heiko Mannsperger; Christian Schmidt; Ulrike Korf; Heinz Höfler; Karl-Friedrich Becker
Journal:  Transl Oncol       Date:  2012-04-01       Impact factor: 4.243

Review 3.  Histopathological markers of treatment response and recurrence risk in ovarian cancers and borderline tumors.

Authors:  S Avril
Journal:  Pathologe       Date:  2017-11       Impact factor: 1.011

4.  uPA-PAI-1 heteromerization promotes breast cancer progression by attracting tumorigenic neutrophils.

Authors:  Bernd Uhl; Laura A Mittmann; Julian Dominik; Roman Hennel; Bojan Smiljanov; Florian Haring; Johanna B Schaubächer; Constanze Braun; Lena Padovan; Robert Pick; Martin Canis; Christian Schulz; Matthias Mack; Ewgenija Gutjahr; Peter Sinn; Jörg Heil; Katja Steiger; Sandip M Kanse; Wilko Weichert; Markus Sperandio; Kirsten Lauber; Fritz Krombach; Christoph A Reichel
Journal:  EMBO Mol Med       Date:  2021-05-16       Impact factor: 12.137

Review 5.  Fibrinolytic System and Cancer: Diagnostic and Therapeutic Applications.

Authors:  Niaz Mahmood; Shafaat A Rabbani
Journal:  Int J Mol Sci       Date:  2021-04-22       Impact factor: 5.923

6.  Overexpression of MMP-3 and uPA with Diminished PAI-1 Related to Metastasis in Ductal Breast Cancer Patients Attending a Public Hospital in Mexico City.

Authors:  Luis Miguel Barajas-Castañeda; Evelin Cortés-Gutiérrez; Francisco Mario García-Rodríguez; Rafael Campos-Rodríguez; Eleazar Lara-Padilla; Fernando Enríquez-Rincón; María Eugenia Castro-Mussot; Paula Figueroa-Arredondo
Journal:  J Immunol Res       Date:  2016-11-15       Impact factor: 4.818

7.  Domain retention in transcription factor fusion genes and its biological and clinical implications: a pan-cancer study.

Authors:  Pora Kim; Leomar Y Ballester; Zhongming Zhao
Journal:  Oncotarget       Date:  2017-11-24

8.  Common protein biomarkers assessed by reverse phase protein arrays show considerable intratumoral heterogeneity in breast cancer tissues.

Authors:  Katharina Malinowsky; Mithu Raychaudhuri; Theresa Buchner; Sabrina Thulke; Claudia Wolff; Heinz Höfler; Karl-Friedrich Becker; Stefanie Avril
Journal:  PLoS One       Date:  2012-07-05       Impact factor: 3.240

Review 9.  Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.

Authors:  Niaz Mahmood; Catalin Mihalcioiu; Shafaat A Rabbani
Journal:  Front Oncol       Date:  2018-02-12       Impact factor: 6.244
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.